Smith Stan 4/A
4/A · MAIA Biotechnology, Inc. · Filed Mar 5, 2025
Insider Transaction Report
Form 4/AAmended
Smith Stan
Director
Transactions
- Purchase
Common Stock
2025-02-24$1.50/sh+50,000$75,000→ 1,180,060 total(indirect: See Footnote) - Purchase
Warrants
2025-02-24$1.87/sh+50,000$93,500→ 50,000 total(indirect: See Footnote)Exercise: $1.87From: 2026-02-24Exp: 2031-02-24→ Common Stock (50,000 underlying)
Footnotes (5)
- [F1]The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on February 24, 2025.
- [F2]These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.
- [F3]This Form 4/A is being filed to correct the "Date Exercisable" and "Expiration Date" in Section 6 of Table II reported in the original Form 4 filed on February 25, 2025 as well as to correct the date of the Securities Purchase Agreement orginally referenced in the footnote 1 and 3 to "February 24, 2025".
- [F4]These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on February 24, 2025. The options are exercisable beginning on the one-year anniversary of the issuance date and expire 6-years after the inital issuance date.
- [F5]These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.